NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease

European Journal of Neuroscience

Volumn 14, Issue 2, 2001, Pages 391-400

  Crocker, Stephen J ^a   Wigle, Nichola ^a   Liston, Peter ^c   Thompson, Charlie S ^a   Lee, Chris J ^a   Xu, Daigen ^d   Roy, Sophie ^d   Nicholson, Donald W ^d   Park, David S ^a   MacKenzie, Alex ^b,c   Korneluk, Robert G ^b,c   Robertson, George S ^a,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Aegera Oncology Inc   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Axotomy; Basal ganglia; Caspase 3; NAIP; Parkinson's disease; Substantia nigra

Indexed keywords

6 HYDROXYDOPA; APOPTOSIS INHIBITOR; CASPASE 3; CYSTEINE PROTEINASE; NEURONAL APOPTOSIS INHIBITORY PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BASAL GANGLION; CELL DEATH; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FOREBRAIN; MALE; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE FIBER TRANSECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

AMPHETAMINE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; CASPASE 3; CASPASES; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; DOPAMINE; FLUORESCENT DYES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MALE; MOVEMENT DISORDERS; NEOSTRIATUM; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; NEURONAL APOPTOSIS-INHIBITORY PROTEIN; NEUROTOXINS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SYMPATHOLYTICS;

EID: 0034883987     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0953-816X.2001.01653.x     Document Type: Article

References (78)

1. Adenovirus in the brain: Recent advances of gene therapy for neurodegenerative diseases
2. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease
3. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons
4. A quantitative study of cell death in the substantia nigra following a mechanical lesion of the medial forebrain bundle
5. Programmed cell death: Does it play a role in Parkinson's disease?
6. Dopaminergic neurons protected from degeneration by GDNF gene therapy
7. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement
8. Apoptosis reduces both the in vitro replication and the in vivo infectivity of a baculovirus
9. Rescue from death but not from functional impairtment caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals
10. D1-Receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression
11. Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration
12. X-linked IAP is a direct inhibitor of cell-death proteases
13. Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4-phenylpyridinum-induced toxicity of cultured fetal rat mesencephalic dopamine neurons
14. Caspase-3-like proteases and 6-hydroxydopamine induced neuronal cell death
15. Involvement of a caspase-3-like cysteine protease in 1-methyl-4- phenylpyridinium-mediated apoptosis of cultured cerebellar granule neurons
16. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
17. Apoptosis in ischemic and reperfused rat myocardium
18. Gene targeting with a replication-defective adenovirus vector
19. A susceptibility locus for Parkinson's disease maps to chromosome 2p13
20. Distribution of striatonigral and stridatopallidal peptidergic neurons in both patch and matrix compartments: An in situ hybridization histochemistry and fluorescent retrograde tracing study
21. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation
22. Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine
23. Protein nitration in Parkinson's disease
24. A new technique for the assay of infectivity of human adenovirus 5 DNA
25. Local transcriptional control of utrophin expression at the neuromuscular synapse
26. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo
27. Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death
28. Inhibition of biogenic amine uptake by hydrogen peroxide: A mechanism
29. Lasting N-terminal phosphorylation of c-June and activation of c-June N-terminal kinases after neuronal injury
30. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
31. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
32. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease
33. Activation of caspase-3 in developmental models of programmed cell death in neurons of the substantia nigra
34. Twin studies and the genetics of Parkinson's disease - A reappraisal
35. Identification and mapping of Casp7, a cysteine protease resembling CPP32 beta, interleukin-1 beta converting enzyme, CED-3
36. The principles of gene therapy for the nervous system
37. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
38. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
39. Environmental risk factors in Parkinson's disease
40. Decreased apoptosis in the brain and premature lethality in CPP32- deficient mice
41. Free radical-generated neurotoxicity of 6-hydroxydopamine
42. The ubiquitin pathway in Parkinson's disease
43. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes
44. The neuronal apoptosis inhibitory protein (NAIP) is a specific caspase-3 and caspase-7 inhibitor
45. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats
46. A clinical and genetic study of familial Parkinson's disease
47. Recent advances on neuronal caspases in development and neurodegeneration
48. Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra
49. Apoptosis induced by Drosophila reaper and grim in a human system. Attenuation by inhibitor of apoptosis proteins (cIAPs)
50. NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways
51. Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells
52. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
53. Early onset Parkinson's disease and childhood environment
54. Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex
55. Quantitative Radioautography for NGF Receptors
56. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle
57. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium
58. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
59. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy
60. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat
61. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion
62. Anatomic and disease specificity of NADH CoQ1 reductase (complex I)
63. Fluoro-Jade: A novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration
64. Genetic complexity and Parkinson's disease
65. A versatile carrier for simply constructed wire knives and microsyringes
66. Hematoxylin/Eosin Staining
67. Evidence for generation of oxidative stress in brain by MPTP: In vitro and in vivo studies in mice
68. A single BIR domain of XIAP sufficient for inhibiting caspases
69. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining
70. Apoptosis in the pathogenesis and treatment of disease
71. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system
72. Injury induced c-Jun expression and phosphorylation in the dopaminergic nigral neurons of the rat: Correlation with neuronal death and modulation by glial cell line-derived neurotrophic factor
73. Inhibitor of apoptosis proteins physically interact with and block apoptosis induced by Drosophila proteins HID and GRIM
74. Cell death and apoptosis regulating proteins in Parkinson's disease - A cautionary note
75. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus
76. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus
77. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6- hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo